International Stem Cell (ISCO) Stock Price, News & Analysis

Company Overview

International Stem Cell Corporation (OTCMKTS:ISCO) is a biotechnology company focused on the development and commercialization of human parthenogenetic stem cells (hpSC) for therapeutic and research applications. Parthenogenetic stem cells are derived from unfertilized human eggs and offer a scalable, ethically noncontroversial source of pluripotent cells. ISCO’s proprietary hpSC lines can be directed to differentiate into a wide variety of cell types, enabling preclinical programs in areas such as neurodegenerative disease, liver disease, diabetes and corneal regeneration.

In addition to its therapeutic pipeline, International Stem Cell maintains a research products division that supplies hpSC lines, differentiated cell populations and media formulations to academic institutions, biotechnology companies and contract research organizations. By licensing its cell-based technology, ISCO aims to foster collaboration across the scientific community and accelerate the development of cell therapy and drug discovery platforms worldwide.

Beyond its core stem cell activities, the company markets consumer skin care products under the Lifeline® brand. Leveraging its expertise in human cell biology, ISCO’s skin care portfolio features anti-aging formulations based on cell-conditioned media, peptides and growth factors designed to support skin rejuvenation. These products are distributed through e-commerce channels and selected retail partners in North America, Europe and Asia.

Founded in 2008 and headquartered in Carlsbad, California, International Stem Cell Corporation was co‐founded by Dr. Michael D. West, a veteran in the field of regenerative medicine. The company operates research facilities in California and Australia, reflecting its commitment to global collaboration and the advancement of parthenogenetic stem cell science. Through ongoing R&D efforts and strategic partnerships, ISCO seeks to translate its proprietary hpSC technology into clinical and commercial successes in the emerging cell therapy market.

Key Stats

• Today's Range: $0.15 to $0.15
• 50-Day Range: $0.12 to $0.18
• 52-Week Range: $0.06 to $0.27
• Volume: 332 shs
• Average Volume: 1,601 shs
• Market Capitalization: $1.18 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ISCO Stock Analysis - Frequently Asked Questions

How have ISCO shares performed this year?

International Stem Cell's stock was trading at $0.0813 at the beginning of 2025. Since then, ISCO stock has increased by 82.0% and is now trading at $0.1480.

How were International Stem Cell's earnings last quarter?

International Stem Cell Corp. (OTCMKTS:ISCO) posted its quarterly earnings data on Thursday, August, 14th. The biotechnology company reported $0.01 earnings per share for the quarter. The biotechnology company earned $2.45 million during the quarter.

How do I buy shares of International Stem Cell?

Shares of ISCO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of International Stem Cell own?

Based on aggregate information from My MarketBeat watchlists, some other companies that International Stem Cell investors own include Canopy Growth (CGC), Aurora Cannabis (ACB), Amarantus Bioscience (AMBS), Fulcrum Therapeutics (FULC), Kutcho Copper (KCCFF), B2Gold (BTG) and Cannabis Wheaton Income (CBWTF).

Company Calendar

• Last Earnings: 8/14/2025
• Today: 10/14/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:ISCO
• CIK: 1355790
• Web: www.internationalstemcell.com
• Phone: (760) 940-6383
• Fax: 760-476-0600
• Employees: 30
• Year Founded: 2001

Profitability

• EPS (Trailing Twelve Months): ($0.04)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$210 thousand
• Net Margins: -3.29%
• Pretax Margin: -2.62%
• Return on Equity: N/A
• Return on Assets: -5.63%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.78
• Quick Ratio: 0.46

Sales & Book Value

• Annual Sales: $9.09 million
• Price / Sales: 0.13
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.49) per share
• Price / Book: -0.30

Miscellaneous

• Outstanding Shares: 8,000,000
• Free Float: 1,324,000
• Market Cap: $1.18 million
• Optionable: Not Optionable
• Beta: -0.02